Search

everythinglearnresearchcommunity

for

Search:↓

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Tofacitinib taken by mouth helps treat hair loss in children.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tofacitinib treatment is used for teenagers with alopecia areata.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Tofacitinib helped regrow hair in a woman with alopecia areata.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

Tofacitinib may help treat severe hair loss, but more research is needed.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.